ABBV-154
Rheumatoid Arthritis
Key Facts
About AbbVie
AbbVie's mission is to discover and deliver transformative medicines that solve serious health issues. Its landmark achievement was building the world's top-selling drug, Humira, into a franchise while successfully navigating its patent expiry through a robust pipeline and strategic acquisitions like Allergan. The company's strategy hinges on sustained leadership in immunology, accelerated growth in oncology and neuroscience, and financial discipline to fuel high R&D investment and shareholder returns.
View full company profileTherapeutic Areas
Other Rheumatoid Arthritis Drugs
| Drug | Company | Phase |
|---|---|---|
| Early Detection Test for Rheumatoid Arthritis | Age Labs | Development |
| Piclidenoson (CF101) | Can Fite Biopharma | Phase II/III |
| ERNA-201 | Eterna Therapeutics | Preclinical |
| Tc99m Tilmanocept | Navidea Biopharmaceuticals | Phase 2/3 |
| Monoclonal Antibody Biosimilar (Anti‑TNF) | USV Biologics Division | Phase 1 |
| Targeted Immunotherapy for Rheumatoid Arthritis (via Arthritis4Cure) | LFB | Pre-clinical |
| EYD-001 (Takinib analog) | EydisBio | Preclinical |
| LFD-200 | Lifordi Immunotherapeutics | Phase 1 |
| MEV-N01 | Mesenbio | Pre-clinical |
| CIT-013 | Citryll | Phase 2a |
| Restem-L | Restem | Phase 2 |
| ASIT Platform | Ahead Therapeutics | Pre-clinical |